Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Schram · SciRah

Researcher profile · Semantic Scholar

A. Schram

Share profile

A. Schram — researcher profile on SciRah

h-index: 39
Works: 178
Citations: 10K

Most-cited papers

Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements
A. Schram, I. Odintsov, Madelyn Espinosa-Cotton, I. Khodos +18 more
2022Cancer Discovery144 citations Open access
Semantic Scholar
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
A. Schram, Koichi Goto, Dong-Wan Kim, T. Macarulla +28 more
2025New England Journal of Medicine124 citations Open access
Semantic Scholar
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
A. Desai, J. Gainor, A. Hegde, A. Schram +20 more
2021Nature Reviews Clinical Oncology120 citations Open access
Semantic Scholar
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
T. Yap, A. Bardia, M. Dvorkin, M. Galsky +16 more
2022JAMA Oncology98 citations Open access
Semantic Scholar
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
V. Subbiah, V. Sahai, Dejan Maglic, Kamil Bruderek +27 more
2023Cancer Discovery92 citations Open access
Semantic Scholar
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Jason C. Chang, M. Offin, C. Falcon, David N. Brown +22 more
2021Clinical Cancer Research86 citations Open access
Semantic Scholar
Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples anti-tumor activity from hyperinsulinemia
A. Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang +48 more
2023Cancer Discovery74 citations Open access
Semantic Scholar
Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
A. Drilon, M. Duruisseaux, Ji-Youn Han, M. Ito +32 more
2021Journal of Clinical Oncology70 citations Open access
Semantic Scholar
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
C. B. Westphalen, D. Martins-Branco, J. Beal, C. Cardone +20 more
2024Annals of Oncology63 citations Open access
Semantic Scholar
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
A. Schram, K. Goto, Dong-Wan Kim, P. Martin-Romano +16 more
2022Journal of Clinical Oncology58 citations
Semantic Scholar
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
A. Schram, N. Colombo, E. Arrowsmith, V. Narayan +19 more
2022JAMA Oncology56 citations Open access
Semantic Scholar
Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
T. Yap, S. Im, A. Schram, A. Sharp +12 more
2022Cancer Research55 citations Open access
Semantic Scholar
Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator
Anna M. Puzio-Kuter, Li-Zhong Xu, M. McBrayer, Romyr Dominique +25 more
2025Cancer Discovery54 citations Open access
Semantic Scholar
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
D. M. Barrios, G. S. Phillips, A. Geisler, S. R. Trelles +18 more
2021Annals of Oncology48 citations Open access
Semantic Scholar
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong-Wan Kim, A. Schram, A. Hollebecque, K. Nishino +14 more
2024Future Oncology44 citations Open access
Semantic Scholar
Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.
A. Schram, E. O'Reilly, G. O'Kane, K. Goto +16 more
2021Journal of Clinical Oncology41 citations
Semantic Scholar
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
M. Borad, A. Schram, R. Kim, Suneel D. Kamath +16 more
2023Journal of Clinical Oncology37 citations
Semantic Scholar
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
Y. Murciano-Goroff, A. Schram, E. Rosen, H. Won +12 more
2022Nature Communications37 citations Open access
Semantic Scholar
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
C. Rolfo, A. Drilon, D. Hong, C. McCoach +21 more
2021British Journal of Cancer35 citations Open access
Semantic Scholar
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
E. Borazanci, A. Schram, E. Garralda, I. Braña +19 more
2022ESMO Open32 citations Open access
Semantic Scholar
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Tripti Shrestha Bhattarai, Tambudzai Shamu, A. Gorelick, Matthew T. Chang +15 more
2022Nature Communications32 citations Open access
Semantic Scholar
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
L. Smyth, G. Batist, F. Meric-Bernstam, P. Kabos +23 more
2021npj Breast Cancer30 citations Open access
Semantic Scholar
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
E. Dumbrava, G. Shapiro, A. Parikh, M. Johnson +13 more
2026New England Journal of Medicine29 citations
Semantic Scholar
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
C. Friedman, B. Manning-Geist, Qin Zhou, Tara E. Soumerai +24 more
2024Nature Medicine27 citations Open access
Semantic Scholar
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
J. Francis, J. Harding, A. Schram, Julia Canestraro +11 more
2021JAMA ophthalmology25 citations Open access
Semantic Scholar
Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
S. Movva, K. Seier, Viswatej Avutu, Lauren B Banks +21 more
2024Clinical Cancer Research20 citations
Semantic Scholar
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors
E. Garralda, A. Schram, P. Bedard, G. Schwartz +8 more
2023The Oncologist20 citations Open access
Semantic Scholar
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S. Walmsley, P. Jonsson, Michael L. Cheng, S. McBride +16 more
2024npj Precision Oncology18 citations Open access
Semantic Scholar
Clinical and Morphologic Characteristics of ERK Inhibitor-Associated Retinopathy
J. Francis, Julia Canestraro, Dianna Haggag-Lindgren, J. Harding +6 more
2021Ophthalmology Retina17 citations
Semantic Scholar
Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma
M. Chui, Jason C. Chang, Yan-Ming Zhang, A. Zehir +6 more
2021JCO Precision Oncology16 citations Open access
Semantic Scholar
Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
T. Yap, A. Schram, Elizabeth K. Lee, F. Simpkins +19 more
2023Molecular Cancer Therapeutics14 citations
Semantic Scholar
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Lisa Werr, D. Plenker, Marcel A. Dammert, C. Lorenz +13 more
2022Molecular Cancer Therapeutics14 citations Open access
Semantic Scholar
Mechanisms of acquired resistance to TRK inhibitors.
Guilherme Harada, N. Choudhury, A. Schram, E. Rosen +14 more
2022Journal of Clinical Oncology13 citations
Semantic Scholar
Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
T. Patil, D. Carrizosa, M. Burkard, K. Reckamp +11 more
2023Cancer Research12 citations
Semantic Scholar
Abstract IA006: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
A. Schram, V. Subbiah, Chih-Yi Liao, Víctor Moreno +45 more
2023Molecular Cancer Therapeutics11 citations
Semantic Scholar
Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors
Mara Rao, Madeline Merrill, Megan Troxel, S. Chiang +3 more
2025JCO Precision Oncology10 citations Open access
Semantic Scholar
Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)
A. Schram, Elizabeth K. Lee, M. Højgaard, F. Simpkins +18 more
2025Cancer Research10 citations
Semantic Scholar
Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
A. Schram, V. Subbiah, R. Sullivan, R. Cosman +13 more
2023Cancer Research10 citations
Semantic Scholar
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
A. Schram, A. Naqash, E. Haura, J. Riess +16 more
2025Clinical Cancer Research9 citations
Semantic Scholar
Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation
A. Schram, G. Shapiro, Melissa L. Johnson, A. Tolcher +12 more
2023Molecular Cancer Therapeutics9 citations
Semantic Scholar
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.
S. Movva, Viswatej Avutu, Ping Chi, M. Dickson +15 more
2023Journal of Clinical Oncology8 citations Open access
Semantic Scholar
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
A. Schram, Suneel D. Kamath, A. El-Khoueiry, M. Borad +12 more
20218 citations
Semantic Scholar
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions
T. Patil, Jessica J. Lin, P. Cheema, D. Carrizosa +23 more
2025JCO Precision Oncology7 citations Open access
Semantic Scholar
Basket Trials: Past, Present, and Future
Y. Murciano-Goroff, Manik Uppal, Monica F. Chen, Guilherme Harada +1 more
2023Annual Review of Cancer Biology7 citations
Semantic Scholar
Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
L. Goyal, M. Borad, V. Subbiah, A. Mahipal +17 more
2021Oral Presentations - Late-Breaking Proffered Abstracts7 citations
Semantic Scholar
Clinical utility and prognostic implications of circulating cell-free DNA in biliary tract cancer
Darren Cowzer, Madison Darmofal, K. Seier, R. Thummalapalli +25 more
2025JCO Precision Oncology6 citations
Semantic Scholar
Emerging Tumor-Agnostic Molecular Targets
Dedipya Bhamidipati, A. Schram
2024Molecular Cancer Therapeutics6 citations Open access
Semantic Scholar
The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study.
Howard A. Burris, S. Ulahannan, E. Haura, S. Ou +14 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
A. Desai, J. Gainor, A. Hegde, A. Schram +20 more
2021Nature Reviews Clinical Oncology6 citations Open access
Semantic Scholar
Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA -mutant HR+HER2- advanced breast cancer: ReDiscover trial.
S. Sammons, C. Saura Manich, A. Italiano, A. Schram +16 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Drilon×13
Invite
A. Drilon — researcher profile on SciRah
V. Subbiah×7
Invite
V. Subbiah — researcher profile on SciRah
Stephen V. Liu×5
Invite
Stephen V. Liu — researcher profile on SciRah
T. Yap×5
Invite
T. Yap — researcher profile on SciRah

×5

Invite

V. Sahai — researcher profile on SciRah

Invite

L. Goyal — researcher profile on SciRah

A. El-Khoueiry×5

Invite

A. El-Khoueiry — researcher profile on SciRah

T. Macarulla×4

Invite

T. Macarulla — researcher profile on SciRah

A. Hollebecque×4

Invite

A. Hollebecque — researcher profile on SciRah

M. Duruisseaux×4

Invite

M. Duruisseaux — researcher profile on SciRah

G. Curigliano×4

Invite

G. Curigliano — researcher profile on SciRah

Suneel D. Kamath×4

Invite

Suneel D. Kamath — researcher profile on SciRah